Skip to main content
. 2019 Sep 5;8(9):1389. doi: 10.3390/jcm8091389

Figure 1.

Figure 1

Proportion of patients achieving a beneficial outcome (i.e., HbA1c reduction ≥1% and/or weight reduction ≥3%) after six months of glucagonlike peptide-1 (GLP-1) receptor agonist initiation according to (A) the prescription label instructions (SmPC) and to (B) the health policy requirements for reimbursement. SmPC, summary of product characteristics; *** p < 0.0001.